Entertainment

Correio newspaper | Fake Ozempic: see differences between the original medicine and the one that led to a woman being hospitalized

[ad_1]

RISK

Fake Ozempic: see differences between the original medicine and the one that led to a woman being hospitalized

Patient bought counterfeit medicine from pharmacy

  • Photo by the author Estadão

Published on October 23, 2024 at 1:47 pm

The pharmaceutical company Novo Nordisk, responsible for producing Ozempic, confirmed that there are fake copies of the medicine being sold illegally and published ways to identify the original medicine. Counterfeits had already been reported, but gained repercussions after a woman was hospitalized after using the deceptive product.

The victim was admitted last Thursday, 17th, to Copa D’Or Hospital, in Rio de Janeiro. The medical bulletin mentions that the patient was admitted “to the emergency room at Copa D’Or hospital, presenting a serious clinical condition that was difficult to identify. She was promptly attended to and the condition was duly treated and reversed.”

“As the patient is undergoing treatment with Ozempic, considering the note that the laboratory responsible for producing the drug recently released about possible falsification of the medicine, there was a suspicion that the patient could have been a victim of the effects of a counterfeit medicine”, concludes the statement. .

The patient was discharged the following day. As a result, the Civil Police went to the pharmacy indicated by the woman as the place to purchase the medicine and seized three boxes of counterfeit medicine. The agency added that the owner of the establishment has already been interviewed and other steps are underway to clarify all the facts.

According to Novo Nordisk, “there are indications that Fiasp FlexTouch insulin pens were re-stickered with Ozempic labels from batch NP5K174 possibly improperly removed from original pens of the medicine.” The pharmaceutical company adds that it cannot guarantee that other batches have not also been falsified.

In addition to the capital of Rio de Janeiro, the company recognized other cases of replacing Ozempic with Fiasp FlexTouch in Paty do Alferes (RJ), Brasília, Anápolis (GO), Curitiba and Belo Horizonte. Currently, an insulin pen can be purchased for less than R$50, while semaglutide is sold for around R$1,000.

The main difference in the applicator of the two medications is the color: the Ozempic pen is light blue, with a gray application button. The Fiasp insulin pen is dark blue, with an orange button.

It is also important to analyze whether the packaging is erased or altered, in a foreign language, with a pharmaceutical appearance (presentation) different from that registered and with incorrect information about the product. The available versions of Ozempic in Brazil are 0.25 mg, 0.5 mg and 1 mg, and there is no “new formula”: the medicine follows the same formulation and packaging since it arrived in the country in 2019.

Novo Nordisk also highlights that its products follow the table of the Medicines Market Regulation Chamber, which regulates the price of medicines in the country. Therefore, any discount or promotion that leaves the medicine priced well below the market should serve as a warning.

Finally, the pharmaceutical company recommends being wary of “sites and channels not licensed by Anvisa for the sale of medicines and which use brand names and/or adopt sales applications and social networks to offer the products”.

If you are not sure about the origin of the product, do not apply it. The recommendation is to contact Novo Nordisk’s Customer Service (SAC) to report what happened and, if desired, deliver samples of the pen to the company for analysis in its laboratory in Denmark. From there, a report on the product is issued.

“Novo Nordisk has already notified Anvisa about the cases, complying with pharmacovigilance requirements, and has closely monitored all cases reported on its channels, in the press and on social networks, within a risk management and minimization plan implemented by the company “, ends the press release.

[ad_2]

Source link

Michelle Williams

I'm Michelle Williams, an enthusiastic author specializing in captivating entertainment content on Rwcglobally.com. With a passion for storytelling and a keen eye for the latest trends, I aim to engage readers with compelling narratives that reflect the dynamic landscape of the entertainment industry. Join me on Rwcglobally.com to explore the world of film, television, music, and more, as we uncover the stories that define contemporary culture.

Post Comment